Alnylam Pharmaceuticals Inc (ALNY)

234.28 +0.66 (+0.28%) USD  |  NASDAQ  |  Jan 03, 16:00
234.30 +0.02 (+0.01%) After-Hours: 20:00
More

Alnylam Pharmaceuticals SG&A Expense (Quarterly): 220.99M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for ALNY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Pfizer Inc 3.244B
BridgeBio Pharma Inc 68.82M
Gilead Sciences Inc 1.433B
Sarepta Therapeutics Inc 128.20M
Regeneron Pharmaceuticals Inc 714.40M